Ranimustine (
INN, marketed under the tradename Cymerin; also known as MCNU) is a
nitrosoureaalkylating agent approved in
Japan for the treatment of chronic myelogenous
leukemia[1] and polycythemia vera.[2]
It has never been filed for
FDA evaluation in the
United States, where it is not marketed.
References
^Kitajima K, Adachi T, Takahashi I, et al. (November 1989). "[Chemotherapy of chronic myelogenous leukemia—VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis]". Gan To Kagaku Ryoho (in Japanese). 16 (11): 3573–9.
PMID2817908.
^Nagai M, Tasaka T, Kamano H, et al. (December 1988). "[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]". Gan To Kagaku Ryoho (in Japanese). 15 (12): 3267–70.
PMID3196045.
(in Japanese)Cymerin サイメリン (PDF) Mitsubishi Tanabe Pharma. October 2007.